AMYT.L ( MKap 50 M€) potentieller Blockbuster mit P3 Daten im 2H19 (Seite 7)
eröffnet am 02.02.19 20:48:07 von
neuester Beitrag 09.01.23 09:01:04 von
neuester Beitrag 09.01.23 09:01:04 von
Beiträge: 88
ID: 1.297.401
ID: 1.297.401
Aufrufe heute: 0
Gesamt: 10.887
Gesamt: 10.887
Aktive User: 0
ISIN: GB00BKLTQ412 · WKN: A2PQ6T
1,9400
EUR
0,00 %
0,0000 EUR
Letzter Kurs 11.01.22 Lang & Schwarz
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6800 | +312,12 | |
| 29,75 | +36,97 | |
| 0,5300 | +17,78 | |
| 325,00 | +13,24 | |
| 0,7900 | +11,27 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5000 | -23,08 | |
| 3,0000 | -24,91 | |
| 0,7500 | -25,00 | |
| 17,850 | -30,00 | |
| 1,5000 | -90,00 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 60.374.761 von sirlacoura am 17.04.19 11:02:30Irgendwie läuft es nicht... Wahrscheinlich müssen wir bis Ende des Jahres warten. Aber es sind jetzt tolle Einstiegskurse.
Antwort auf Beitrag Nr.: 60.345.787 von Chancen1904 am 12.04.19 23:20:49
Zahlen sollten den Kurs einen nachhaltigen Schub gen Norden geben
https://de.advfn.com/p.php?pid=nmona&article=79713087
Antwort auf Beitrag Nr.: 60.325.327 von sirlacoura am 10.04.19 19:17:57NOTICE OF RESULTS
Released : 12 Apr 2019 10:04
RNS Number : 0506W
Amryt Pharma PLC
12 April 2019
12 April 2019
AIM: AMYT
Euronext Growth : AYP
Amryt Pharma plc
Notice of Results
Amryt Pharma plc announces that its results for the year ended 31 December 2018 will be issued on Wednesday 17 April 2019.
- Ends -
Enquiries:
Released : 12 Apr 2019 10:04
RNS Number : 0506W
Amryt Pharma PLC
12 April 2019
12 April 2019
AIM: AMYT
Euronext Growth : AYP
Amryt Pharma plc
Notice of Results
Amryt Pharma plc announces that its results for the year ended 31 December 2018 will be issued on Wednesday 17 April 2019.
- Ends -
Enquiries:
Antwort auf Beitrag Nr.: 60.250.263 von Venus1 am 01.04.19 22:18:50Hallo, sicher ? Ist nichts zu finden diesbzgl.
Am 10. April kommen News bezüglich Verlauf 2018 und Update von AP101 EASE Phase III trial.. Habe kürzlich ein Mail von der Company erhalten. Gruss
Trading Spotlight
Antwort auf Beitrag Nr.: 60.200.493 von Readyx am 26.03.19 18:04:11No news.
Boden evtl bei 12,5
Boden evtl bei 12,5
Hat hier Jemand eine Erklärung für das ständige abschmiern? Gruss
ruhig hier, soll mal lieber die Richtung wechseln
Antwort auf Beitrag Nr.: 59.985.373 von Danny767 am 28.02.19 12:23:48Top. Läuft bestens. Irgendwann entdeckt der Markt die Aktie und dann geht's ab
KeywordCompanyEPIC/TIDMSEDOL/ISINNews
Search
Price
Announcements
Fundamentals
News
Article
RSS
Amryt Pharma PLC (AMYT)
Add to Alerts list
Print Mail a friend
Thursday 28 February, 2019
Amryt Pharma PLC
Update on AP101 EASE Phase III trial
RNS Number : 3552R
Amryt Pharma PLC
28 February 2019
28 February 2019
AIM: AMYT
Amryt Pharma plc
("Amryt" or the "Company")
Update on AP101 EASE Phase III trial
IDMC recommends study can enrol children and infants aged from 21 days to 4 years
Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa ("EB").
Following an assessment by the trial's Independent Data Monitoring Committee ("IDMC"), the Company can now enrol infants and children with EB between the ages of 21 days to 4 years of age in to the trial. The IDMC's analysis was conducted using pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older). This follows the announcement of the unblinded interim efficacy analysis in January.
Amryt will begin the recruitment process for infants and children into EASE immediately. The EASE trial is the largest ever global Phase III study conducted in patients with EB and Amryt expects top-line data read out in H2 2019.
EB is a devastating, rare genetic skin disorder that can cause skin to blister and tear from the slightest friction or trauma and can, in some cases, cause blistering and erosion of the epithelial lining of internal organs. EB is chronic, potentially disfiguring and life limiting. There are approximately 500,000 people living with EB worldwide and there are currently no approved treatments.1 It is estimated that the market potential for AP101 is more than €1 billion.
Joe Wiley, CEO of Amryt Pharma, commented: "Extending the age eligibility criteria for this trial is positive news and a significant step forward in addressing the unmet need in this devastating condition, which is present from birth in most cases. This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphan diseases."
Enquiries:
Amryt Pharma plc
+353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital
+44 (0) 20 7408 4090
NOMAD and Joint Broker
Edward Mansfield, Mark Percy, Daniel Bush
Stifel
+44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy
+353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Consilium Strategic Communications
+44 (0) 20 3709 5700
Matthew Neal, David Daley, Nicholas Brown
1https://www.debra.org.uk/what-is-eb/what-is-eb
About Amryt
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.
Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels, heart attacks and strokes, even at a very young age if not properly diagnosed or receiving adequate treatment. Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.
Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.
Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment. It is currently in Phase III clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, please visit amrytpharma.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDCKODNBBKBOBB
FTSE 100 FTSE All-Share FTSE 250 AIM
chart
1 Day * | 1 Week | 3 Months | 1 Year Loss: -0.71%
Headlines
28-Feb-2019 11:00 AM
Market Movers - Top risers and fallers at 11:00
FTSE 100 Rentokil Initial 343.90 +4.53% Evraz 565.30 +1.60% St James's Place ...
28-Feb-2019 10:17 AM
Bakkavor profits up 39%, but warns low consumer confidence, rising costs will bite into margins
28-Feb-2019 10:09 AM
Hunting resumes dividend after profits rise amid US onshore-centric drilling activity
28-Feb-2019 10:02 AM
Market Movers - Top risers and fallers between 09:00 and 10:00
28-Feb-2019 10:01 AM
Inchcape profits plunge as weaker conditions in the UK, Australia retail markets hurt performance
28-Feb-2019 10:00 AM
Market Movers - Top risers and fallers at 10:00
»Hastings grows profits despite pressure on premiums »Amigo profits jump on stronger loan book »Genus swings to loss as African Swine Fever in China, asset writedowns weigh »DIY Group Grafton profits up 17% on 'fast' growth in Irish, Dutch markets »Howden Joinery Group profits pressured by one-off pension charge »Market Movers - Top risers and fallers between 08:00 and 09:00 »Market Movers - Top risers and fallers at 09:00 »Broker Forecast - Deutsche Bank issues a broker note on ITV PLC »CRH posts flat profits as as higher costs, bad weather hurt growth
More headlines
Company finder
#ABCDEFGHIJKLMNOPQRSTUVWXYZ
Forthcoming announcements
28-Feb-2019 Company Events - Today's Events
28-Feb-2019 Company Events - Tomorrow's Events
28-Feb-2019 Company Events - 7 Days Ahead Events
28-Feb-2019 Company Events - Month Ahead Events
Latest directors dealings
01:51 pm
Search
Price
Announcements
Fundamentals
News
Article
RSS
Amryt Pharma PLC (AMYT)
Add to Alerts list
Print Mail a friend
Thursday 28 February, 2019
Amryt Pharma PLC
Update on AP101 EASE Phase III trial
RNS Number : 3552R
Amryt Pharma PLC
28 February 2019
28 February 2019
AIM: AMYT
Amryt Pharma plc
("Amryt" or the "Company")
Update on AP101 EASE Phase III trial
IDMC recommends study can enrol children and infants aged from 21 days to 4 years
Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa ("EB").
Following an assessment by the trial's Independent Data Monitoring Committee ("IDMC"), the Company can now enrol infants and children with EB between the ages of 21 days to 4 years of age in to the trial. The IDMC's analysis was conducted using pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older). This follows the announcement of the unblinded interim efficacy analysis in January.
Amryt will begin the recruitment process for infants and children into EASE immediately. The EASE trial is the largest ever global Phase III study conducted in patients with EB and Amryt expects top-line data read out in H2 2019.
EB is a devastating, rare genetic skin disorder that can cause skin to blister and tear from the slightest friction or trauma and can, in some cases, cause blistering and erosion of the epithelial lining of internal organs. EB is chronic, potentially disfiguring and life limiting. There are approximately 500,000 people living with EB worldwide and there are currently no approved treatments.1 It is estimated that the market potential for AP101 is more than €1 billion.
Joe Wiley, CEO of Amryt Pharma, commented: "Extending the age eligibility criteria for this trial is positive news and a significant step forward in addressing the unmet need in this devastating condition, which is present from birth in most cases. This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphan diseases."
Enquiries:
Amryt Pharma plc
+353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital
+44 (0) 20 7408 4090
NOMAD and Joint Broker
Edward Mansfield, Mark Percy, Daniel Bush
Stifel
+44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
Davy
+353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Consilium Strategic Communications
+44 (0) 20 3709 5700
Matthew Neal, David Daley, Nicholas Brown
1https://www.debra.org.uk/what-is-eb/what-is-eb
About Amryt
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.
Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels, heart attacks and strokes, even at a very young age if not properly diagnosed or receiving adequate treatment. Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.
Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.
Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment. It is currently in Phase III clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1 billion.
In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, please visit amrytpharma.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDCKODNBBKBOBB
FTSE 100 FTSE All-Share FTSE 250 AIM
chart
1 Day * | 1 Week | 3 Months | 1 Year Loss: -0.71%
Headlines
28-Feb-2019 11:00 AM
Market Movers - Top risers and fallers at 11:00
FTSE 100 Rentokil Initial 343.90 +4.53% Evraz 565.30 +1.60% St James's Place ...
28-Feb-2019 10:17 AM
Bakkavor profits up 39%, but warns low consumer confidence, rising costs will bite into margins
28-Feb-2019 10:09 AM
Hunting resumes dividend after profits rise amid US onshore-centric drilling activity
28-Feb-2019 10:02 AM
Market Movers - Top risers and fallers between 09:00 and 10:00
28-Feb-2019 10:01 AM
Inchcape profits plunge as weaker conditions in the UK, Australia retail markets hurt performance
28-Feb-2019 10:00 AM
Market Movers - Top risers and fallers at 10:00
»Hastings grows profits despite pressure on premiums »Amigo profits jump on stronger loan book »Genus swings to loss as African Swine Fever in China, asset writedowns weigh »DIY Group Grafton profits up 17% on 'fast' growth in Irish, Dutch markets »Howden Joinery Group profits pressured by one-off pension charge »Market Movers - Top risers and fallers between 08:00 and 09:00 »Market Movers - Top risers and fallers at 09:00 »Broker Forecast - Deutsche Bank issues a broker note on ITV PLC »CRH posts flat profits as as higher costs, bad weather hurt growth
More headlines
Company finder
#ABCDEFGHIJKLMNOPQRSTUVWXYZ
Forthcoming announcements
28-Feb-2019 Company Events - Today's Events
28-Feb-2019 Company Events - Tomorrow's Events
28-Feb-2019 Company Events - 7 Days Ahead Events
28-Feb-2019 Company Events - Month Ahead Events
Latest directors dealings
01:51 pm
Durchsuchen
